<?xml version="1.0" encoding="UTF-8"?>
<html>
   <head/>
   <body>
      <div class="hl7Message">
         <p>MSH|^~\&amp;|NIST Test Lab APP|NIST Lab Facility||NIST EHR Facility|20110601192504-0800||ORU^R01^ORU_R01|LRI_4.1_3.1-NG_FRU<br/>|D|2.5.1|||AL|NE|||||LRI_Common_Component^^2.16.840.1.113883.9.16^ISO~LRI_NG_Component^^2.16.840.1.113883.9.13^ISO~LRI_F<br/>RU_Component^^2.16.840.1.113883.9.83^ISO<br/>
         </p>
         <p>PID|1||PATID1234^^^NIST MPI^MR||Jones^William^A^^^^L||19610627|M||2106-3^White^HL70005||||||||PATID1234^^^NIST MPI^MR<br/>
         </p>
         <p>ORC|RE|ORD723222-4^NIST EHR|R-783274-4^NIST Lab Filler|GORD874211^NIST EHR||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^<br/>^^NPI<br/>
         </p>
         <p>OBR|1|ORD723222-4^NIST EHR|R-783274-4^NIST Lab Filler|625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE <br/>STOOL^99USL^^^Stool Culture|||20110530123551-0800|||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI||||||20110531160428<br/>-0800|||F|||10092000194^Hamlin^Pafford^^^^^^NPI^L^^^NPI~2129416824<br/>
         </p>
         <p>OBX|1|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^^^Stool Culture|1|103429008^Enterohemorrhagic Escherichia<br/> coli, serotype O157:H7^SCT^^^^^^Shiga toxin producing E. coli O157:H7 isolated|||A|||F|||20110530123551-0800|||||201106<br/>01130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phi<br/>l^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>NTE|1||Susceptibility testing for E.coli is not performed, because antibiotics should not be used to treat this infecti<br/>on. There is no evidence that treatment with antibiotics is helpful, and taking antibiotics may increase the risk of hem<br/>olytic-uremic syndrome (HUS). Antidiarrheal agents like Imodium® may also increase that risk. Non-specific supportive th<br/>erapy, including hydration, is important. <br/>
         </p>
         <p>OBX|2|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^^^Stool Culture|2|398567006^Salmonella I, group O:4^SCT^^<br/>^^^^Salmonella I, group O:4 isolated|||A|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^<br/>XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>NTE|1||Salmonella gastrointestinal infections usually resolve in 5-7 days and most do not require treatment other than <br/>oral fluids. Persons with severe diarrhea may require rehydration with intravenous fluids. Antibiotic therapy can prolon<br/>g the duration of excretion of non-typhoidal Salmonella and is recommended only for patients with severe illness (e.g., <br/>those with severe diarrhea, high fever, bloodstream infection, or who need hospitalization) or those at risk of severe d<br/>isease or complications, including young infants, older adults (over 65 years old) and immunocompromised persons. Antibi<br/>otic resistance is increasing among some Salmonella bacteria; therefore, susceptibility testing can help guide appropria<br/>te therapy. Choices for antibiotic therapy for severe infections include fluoroquinolones, third-generation cephalospori<br/>ns, and ampicillin (for susceptible infections).<br/>
         </p>
         <p>OBX|3|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^^^Stool Culture|3|85729005^Shigella flexneri^SCT^^^^^^Shi<br/>gella flexneri isolated|||A|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D98713<br/>27|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>NTE|1||Antibiotic treatment is recommended for patients with severe disease, bloody diarrhea, or compromised immune sys<br/>tems. Resistance to traditional first-line drugs like ampicillin and trimethoprim-sulfamethoxazole is common, and resist<br/>ance to some other antibiotics is increasing. With this in mind, antibiotic susceptibility testing can help guide approp<br/>riate therapy. When an ampicillin- or trimethroprim-sulfamethoxazole-resistant strain is isolated, choices for therapy i<br/>nclude fluoroquinolones, ceftriaxone, and azithromycin. <br/>
         </p>
         <p>SPM|1|S-2015-66&amp;GoodHealthC_EHR^S-9911-33&amp;NIST Lab Filler||119339001^Stool specimen^SCT^^^^^^Stool|||||||||||||20110530<br/>123551-0800<br/>
         </p>
         <p>ORC|RE||R-783274-6^NIST Lab Filler|GORD874211^NIST EHR||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI<br/>
         </p>
         <p>OBR|2||R-783274-6^NIST Lab Filler|50545-3^Bacterial susceptibility panel in Isolate by Minimum inhibitory concentration<br/> (MIC)^LN^^^^^^Bacteria susceptibility|||20110530123551-0800||||G|||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI||||||20<br/>110601140428-0800|||F|625-4&amp;Bacteria identified in Stool by Culture&amp;LN&amp;&amp;&amp;&amp;&amp;&amp;Stool Culture^2||10092000194^Hamlin^Pafford^<br/>^^^^^NPI^L^^^NPI|ORD723222-4&amp;NIST EHR^R-783274-4&amp;NIST Lab Filler<br/>
         </p>
         <p>OBX|1|SN|28-1^Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|&lt;^0.06|ug/mL^^UCUM||S|||F|||20<br/>110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90<br/>067^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>OBX|2|SN|267-5^Gentamicin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|^0.05|ug/mL^^UCUM||S|||F|||20<br/>110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90<br/>067^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>OBX|3|SN|185-9^Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|^0.05|ug/mL^^UCUM||S|||F||<br/>|20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA<br/>^90067^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>ORC|RE||R-783274-7^NIST Lab Filler|GORD874211^NIST EHR||||||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI<br/>
         </p>
         <p>OBR|3||R-783274-7^NIST Lab Filler|50545-3^Bacterial susceptibility panel in Isolate by Minimum inhibitory concentration<br/> (MIC)^LN^^^^^^Bacteria susceptibility|||20110530123551-0800||||G|||||5742200012^Radon^Nicholas^^^^^^NPI^L^^^NPI||||||20<br/>110601192428-0800|||C|625-4&amp;Bacteria identified in Stool by Culture&amp;LN&amp;&amp;&amp;&amp;&amp;&amp;Stool Culture^3||10092000194^Hamlin^Pafford^<br/>^^^^^NPI^L^^^NPI|ORD723222-4&amp;NIST EHR^R-783274-4&amp;NIST Lab Filler<br/>
         </p>
         <p>OBX|1|SN|28-1^Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|&lt;^16|ug/mL^^UCUM||I|||F|||2011<br/>0530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^9006<br/>7^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>OBX|2|SN|516-5^Trimethoprim+​Sulfamethoxazole [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|^2^/^38|u<br/>g/mL^^UCUM||S|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test P<br/>ark^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
         <p>OBX|3|SN|185-9^Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN^^^^^^CIPROFLOXACIN|1|^0.05|u<br/>g/mL^^UCUM||S|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^CLIA^XX^^^24D9871327|2070 Test P<br/>ark^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^NIST-AA-1^L^^^DN||||RSLT<br/>
         </p>
      </div>
   </body>
</html>